Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience.
Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience.
复制标题
DOI：
10.3346/jkms.2021.36.e107
复制
发表时间：
2021-04-12
影响因子：
4.5
通讯作者：
Peck KR
中科院分区：
文献类型：
--
作者：
Kim SH;Wi YM;Yun SY;Ryu JS;Shin JM;Lee EH;Seo KH;Lee SH;Peck KR
韩国已开始为医护人员接种2019冠状病毒病疫苗。为了调查每种疫苗第一剂的不良事件（ae），在三级医院接种疫苗后7天内每天收集任何症状。我们发现1,403例ChAdOx1 nCoV-19受体中有1,301例报告不良反应，80例BNT162b2受体中有38例报告不良反应（90.9%比52.5%）：注射部位疼痛（77.7%比51.2%）、肌痛（60.5%比11.2%）、疲劳（50.7%比7.5%）、头痛（47.4%比7.5%）和发烧（36.1%比5%；P < 0.001）。年轻医护人员报告的ChAdOx1 nCoV-19的ae多于BNT162b2。未观察到过敏反应的发生。仅有1例严重AE因严重呕吐住院，且完全康复。总之，报告的ae在ChAdOx1 nCoV-19受体中比在BNT162b2受体中更常见。然而，大多数报道的ae的严重程度为轻度至中度。为促进广泛接种疫苗，需要对预期的不良反应进行充分的解释和准备。
Coronavirus disease 2019 vaccinations for healthcare workers (HCWs) have begun in South Korea. To investigate adverse events (AEs) of the first dose of each vaccine, any symptom was collected daily for seven days after vaccination in a tertiary hospital. We found that 1,301 of 1,403 ChAdOx1 nCoV-19 recipients and 38 of 80 BNT162b2 recipients reported AEs respectively (90.9% vs. 52.5%): injection-site pain (77.7% vs. 51.2%), myalgia (60.5% vs. 11.2%), fatigue (50.7% vs. 7.5%), headache (47.4% vs. 7.5%), and fever (36.1% vs. 5%; P < 0.001 for all). Young HCWs reported more AEs with ChAdOx1 nCoV-19 than with BNT162b2. No incidences of anaphylaxis were observed. Only one serious AE required hospitalization for serious vomiting, and completely recovered. In conclusion, reported AEs were more common in recipients with ChAdOx1 nCoV-19 than in those with BNT162b2. However, most of the reported AEs were mild to moderate in severity. Sufficient explanation and preparation for expected AEs required to promote widespread vaccination.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
DOI：
10.1016/s0140-6736(21)00432-3
发表时间：
2021-03-06
期刊：
Lancet (London, England)
影响因子：
--
作者：
Voysey M;Costa Clemens SA;Madhi SA;Weckx LY;Folegatti PM;Aley PK;Angus B;Baillie VL;Barnabas SL;Bhorat QE;Bibi S;Briner C;Cicconi P;Clutterbuck EA;Collins AM;Cutland CL;Darton TC;Dheda K;Dold C;Duncan CJA;Emary KRW;Ewer KJ;Flaxman A;Fairlie L;Faust SN;Feng S;Ferreira DM;Finn A;Galiza E;Goodman AL;Green CM;Green CA;Greenland M;Hill C;Hill HC;Hirsch I;Izu A;Jenkin D;Joe CCD;Kerridge S;Koen A;Kwatra G;Lazarus R;Libri V;Lillie PJ;Marchevsky NG;Marshall RP;Mendes AVA;Milan EP;Minassian AM;McGregor A;Mujadidi YF;Nana A;Padayachee SD;Phillips DJ;Pittella A;Plested E;Pollock KM;Ramasamy MN;Ritchie AJ;Robinson H;Schwarzbold AV;Smith A;Song R;Snape MD;Sprinz E;Sutherland RK;Thomson EC;Török ME;Toshner M;Turner DPJ;Vekemans J;Villafana TL;White T;Williams CJ;Douglas AD;Hill AVS;Lambe T;Gilbert SC;Pollard AJ;Oxford COVID Vaccine Trial Group
通讯作者：
Oxford COVID Vaccine Trial Group
DOI：
10.15585/mmwr.mm7008e3
发表时间：
2021-02-26
期刊：
MMWR. Morbidity and mortality weekly report
影响因子：
--
作者：
Gee J;Marquez P;Su J;Calvert GM;Liu R;Myers T;Nair N;Martin S;Clark T;Markowitz L;Lindsey N;Zhang B;Licata C;Jazwa A;Sotir M;Shimabukuro T
通讯作者：
Shimabukuro T
DOI：
10.1016/s0140-6736(20)32466-1
发表时间：
2021-12-19
期刊：
Lancet (London, England)
影响因子：
--
作者：
Ramasamy MN;Minassian AM;Ewer KJ;Flaxman AL;Folegatti PM;Owens DR;Voysey M;Aley PK;Angus B;Babbage G;Belij-Rammerstorfer S;Berry L;Bibi S;Bittaye M;Cathie K;Chappell H;Charlton S;Cicconi P;Clutterbuck EA;Colin-Jones R;Dold C;Emary KRW;Fedosyuk S;Fuskova M;Gbesemete D;Green C;Hallis B;Hou MM;Jenkin D;Joe CCD;Kelly EJ;Kerridge S;Lawrie AM;Lelliott A;Lwin MN;Makinson R;Marchevsky NG;Mujadidi Y;Munro APS;Pacurar M;Plested E;Rand J;Rawlinson T;Rhead S;Robinson H;Ritchie AJ;Ross-Russell AL;Saich S;Singh N;Smith CC;Snape MD;Song R;Tarrant R;Themistocleous Y;Thomas KM;Villafana TL;Warren SC;Watson MEE;Douglas AD;Hill AVS;Lambe T;Gilbert SC;Faust SN;Pollard AJ;Oxford COVID Vaccine Trial Group
通讯作者：
Oxford COVID Vaccine Trial Group
DOI：
10.1056/nejmoa2101765
发表时间：
2021-04-15
期刊：
The New England journal of medicine
影响因子：
--
作者：
Dagan N;Barda N;Kepten E;Miron O;Perchik S;Katz MA;Hernán MA;Lipsitch M;Reis B;Balicer RD
通讯作者：
Balicer RD